Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV.
The Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma (KS), an important cause of morbidity and mortality in immunocompromised patients. KSHV interaction with the cell membrane triggers activation of specific intracellular signal transduction pathways to facilitate virus entry, nuclear trafficking, and ultimately viral oncogene expression. Extracellular heat shock protein 90 localizes to the cell surface (csHsp90) and facilitates signal transduction in cancer cell lines, but whether csHsp90 assists in the coordination of KSHV gene expression through these or other mechanisms is unknown. Using a recently characterized non-permeable inhibitor specifically targeting csHsp90 and Hsp90-specific antibodies, we show that csHsp90 inhibition suppresses KSHV gene expression during de novo infection, and that this effect is mediated largely through the inhibition of mitogen-activated protein kinase (MAPK) activation by KSHV. Moreover, we show that targeting csHsp90 reduces constitutive MAPK expression and the release of infectious viral particles by patient-derived, KSHV-infected primary effusion lymphoma cells. These data suggest that csHsp90 serves as an important co-factor for KSHV-initiated MAPK activation and provide proof-of-concept for the potential benefit of targeting csHsp90 for the treatment or prevention of KSHV-associated illnesses.
Qin
Zhiqiang
Z
Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
DeFee
Michael
M
Isaacs
Jennifer S
JS
Parsons
Chris
C
D015967:Gene Expression Regulation, Viral; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D019288:Herpesvirus 8, Human / Q000472:pathogenicity*; D054884:Host-Pathogen Interactions; D006801:Humans; D008214:Lymphocytes / Q000821:virology; D008223:Lymphoma / Q000821:virology; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D012514:Sarcoma, Kaposi / Q000821:virology
D018841:HSP90 Heat-Shock Proteins; D020928:Mitogen-Activated Protein Kinases
J Clin Oncol. 2005 Feb 10;23(5):982-9
15572730
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51
10200299
Nat Immunol. 2001 Apr;2(4):338-45
11276205
Cancer. 2006 Nov 1;107(9):2282-90
16998933
J Virol. 2004 Apr;78(8):4207-23
15047836
J Biol Chem. 2004 May 21;279(21):22483-9
15004035
Cancer Cell. 2006 Aug;10(2):133-43
16904612
J Infect Dis. 2008 Jul 1;198(1):23-30
18491970
N Engl J Med. 2008 Jan 31;358(5):535-6; author reply 536
18234764
J Virol. 2002 Mar;76(6):2634-40
11861829
Science. 1994 Dec 16;266(5192):1865-9
7997879
Virology. 2007 May 25;362(1):109-19
17258257
Cell Microbiol. 2003 Mar;5(3):165-74
12614460
J Virol. 2005 Jun;79(11):7255-61
15890964
Clin Cancer Res. 2006 Jan 15;12(2):584-90
16428504
Antivir Chem Chemother. 2005;16(2):135-46
15889536
J Gen Virol. 2006 May;87(Pt 5):1139-1144
16603514
EMBO J. 2006 Oct 18;25(20):5015-25
17024179
J Virol. 1997 Jan;71(1):715-9
8985403
J Virol. 2006 Feb;80(3):1167-80
16414994
J Infect Dis. 2002 Jun 15;185(12):1736-44
12085319
Virology. 2008 Sep 30;379(2):234-44
18684478
Mol Biol Cell. 2000 May;11(5):1585-95
10793137
J Virol. 2001 Dec;75(23):11583-93
11689640
J Virol. 2005 Apr;79(8):4557-67
15795242
N Engl J Med. 2005 Mar 31;352(13):1317-23
15800227
Nat Cell Biol. 2004 Jun;6(6):507-14
15146192
Cancer. 2004 Jul 15;101(2):317-24
15241829
Blood. 1995 Aug 15;86(4):1276-80
7632932
Transplant Rev (Orlando). 2008 Oct;22(4):252-61
18656341
N Engl J Med. 2007 Sep 27;357(13):1352-3
17898112
J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):678-83
15167286
AIDS. 2000 Sep 29;14(14):2109-16
11061651
Nat Med. 2006 Aug;12(8):908-16
16862153
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11318-22
16844778
J Virol. 2005 Aug;79(16):10740-9
16051866
PLoS Pathog. 2010 Jan 29;6(1):e1000742
20126446
J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8
12890756
Cancer Res. 2008 Oct 15;68(20):8361-8
18922908
AIDS. 2000 Sep 8;14(13):1907-10
10997393
J Virol. 2007 Apr;81(8):3949-68
17287275
Res Virol. 1996 Sep-Oct;147(5):267-75
8880996
Arch Dermatol Res. 1997 Jun;289(7):421-8
9248622
Blood. 1996 Jul 1;88(1):297-301
8704186
J Clin Invest. 2006 Jul;116(7):1963-73
16794734
Virology. 2001 Apr 10;282(2):245-55
11289807
Hematol Oncol Clin North Am. 2003 Jun;17(3):747-62
12852654
Science. 1988 Oct 21;242(4877):430-3
2459779
J Cutan Pathol. 2005 Jan;32(1):21-7
15660651
N Engl J Med. 1995 May 4;332(18):1186-91
7700311
Virology. 2008 Feb 5;371(1):139-54
17964626
Nat Rev Cancer. 2009 Jan;9(1):28-39
19104514
J Clin Invest. 2004 Jan;113(1):124-36
14702116
J Virol. 2005 Aug;79(16):10308-29
16051824
J Gen Virol. 2006 Apr;87(Pt 4):795-802
16528027
Cancer Sci. 2007 Oct;98(10):1536-9
17645779
Oncogene. 2008 Apr 10;27(17):2478-87
17968312
J Virol. 2007 Aug;81(16):8730-41
17522206
Blood. 2007 Mar 1;109(5):2165-73
17082322
Cancer Treat Rev. 2006 Oct;32(6):445-55
16860939
Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):395-402
17656146
N Engl J Med. 1999 Apr 8;340(14):1063-70
10194235
Int J Cancer. 2008 Jul 1;123(1):187-94
18435450
J Leukoc Biol. 2010 Jan;87(1):25-34
20052801
PLoS Pathog. 2007 Mar;3(3):e44
17397260
Clin Cancer Res. 2008 Jun 1;14(11):3456-61
18519777
Antimicrob Agents Chemother. 2004 Mar;48(3):867-72
14982777
J Pathol. 2006 Jan;208(2):187-98
16362980